This research program seeks to devise new strategies to rationally inhibit gene expression mediated by transcription factors (TFs). The strategy is to design modular polyamide DNA minor binding agents that potently and specifically inhibit TF binding to gene promoters and disrupt gene expression. For this purpose, a representative of the Ets oncogenic protein family Elk-1, which binds a serum response element (SRE) contained within the c-fos promoter, was chosen as a model TF. Interference with the binding of Elk-1 to the SRE will be quantitatively measured by mobility shift assays, to assess a polyamide's ability to inhibit TF/DNA complexes. Quantitative footprint analysis will be used to determine where polyamides bind on the SRE promoter element and also the strength of the binding. Polyamides that are potent and specific inhibitors of Elk-1/SRE complex formation will be evaluated for their ability to inhibit transcriptional activation from the c-fos promoter in cell-free and cellular assays. Promising agents will be evaluated for their ability to interfere with a neoplastic phenotype associated with c-fos gene expression. In parallel, polyamides will be optimized for cellular activity while maintaining target specificity.
Specific aims :
Aim1. Identification of polyamide DNA minor groove binding agents that interfere with the binding of Elk-1 to the c-fos promoter under cell-free conditions.
Aim2. Effects of polyamide DNA minor groove binding agents on Elk-1 mediated gene expression of the c-fos promoter under cell-free conditions.
Aim3. Effects of polyamide DNA minor groove binding agents on Elk-1 mediated gene expression of the c-fos promoter in intact cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA080939-03
Application #
6626692
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Program Officer
Lees, Robert G
Project Start
2001-01-09
Project End
2004-12-31
Budget Start
2003-01-01
Budget End
2003-12-31
Support Year
3
Fiscal Year
2003
Total Cost
$327,891
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Wu, Jianguo; Ling, Xiang; Pan, Dalin et al. (2005) Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem 280:9745-51
Philips, Brian J; Chang, Aileen Y; Dervan, Peter B et al. (2005) DNA damage effects of a polyamide-CBI conjugate in SV40 virions. Mol Pharmacol 67:877-82
Dziegielewska, Barbara; Kowalski, David; Beerman, Terry A (2004) SV40 DNA replication inhibition by the monofunctional DNA alkylator Et743. Biochemistry 43:14228-37
Wang, Yong-Dong; Dziegielewski, Jaroslaw; Wurtz, Nicholas R et al. (2003) DNA crosslinking and biological activity of a hairpin polyamide-chlorambucil conjugate. Nucleic Acids Res 31:1208-15
Wang, Yong-Dong; Dziegielewski, Jaroslaw; Chang, Aileen Y et al. (2002) Cell-free and cellular activities of a DNA sequence selective hairpin polyamide-CBI conjugate. J Biol Chem 277:42431-7